Body mass index-associated responses to an ABVD-like regimen in newly-diagnosed patients with Hodgkin lymphoma
Background: The role of body mass index (BMI) in the treatment outcomes of lymphoma patients is controversial. While investigating the efficacy of ABVD-like regimen in Hodgkin lymphoma (HL) patients, we observed that obese patients had poor responses. To better understand this clinical phenomenon, w...
Main Authors: | Min Hu, Yiduo Ding, Haizhou Zhang, Wei Guo, Yun Li, Zhengming Jin, Changju Qu, Fan Xia |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2023.1195907/full |
Similar Items
-
A case of blood triglyceride increased induced by ABVD therapy for classical Hodgkin lymphoma
by: Ryo Yonezawa, et al.
Published: (2023-01-01) -
Baseline prognostic predictors in classical Hodgkin Lymphoma: a retrospective, single-center analysis on patients treated with PET/CT-guided ABVD
by: Alessandro Cellini, et al.
Published: (2024-09-01) -
Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
by: Marc P. E. André, et al.
Published: (2020-09-01) -
Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort studyResearch in context
by: Marriam Mponda, et al.
Published: (2024-03-01) -
Invited commentary on “The impact of bleomycin deficit on survival in Hodgkin's lymphoma patients: A retrospective study”
by: Pritish Chandra Patra
Published: (2024-01-01)